IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v417y2002i6886d10.1038_417254a.html
   My bibliography  Save this article

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Author

Listed:
  • M. B. Pepys

    (Royal Free and University College Medical School)

  • J. Herbert

    (Royal Free and University College Medical School)

  • W. L. Hutchinson

    (Royal Free and University College Medical School)

  • G. A. Tennent

    (Royal Free and University College Medical School)

  • H. J. Lachmann

    (Royal Free and University College Medical School)

  • J. R. Gallimore

    (Royal Free and University College Medical School)

  • L. B. Lovat

    (Royal Free and University College Medical School)

  • T. Bartfai

    (F Hoffmann-La Roche Ltd
    The Scripps Research Institute)

  • A. Alanine

    (F Hoffmann-La Roche Ltd)

  • C. Hertel

    (F Hoffmann-La Roche Ltd)

  • T. Hoffmann

    (F Hoffmann-La Roche Ltd)

  • R. Jakob-Roetne

    (F Hoffmann-La Roche Ltd)

  • R. D. Norcross

    (F Hoffmann-La Roche Ltd)

  • J. A. Kemp

    (F Hoffmann-La Roche Ltd)

  • K. Yamamura

    (Kumamoto University)

  • M. Suzuki

    (Kumamoto University)

  • G. W. Taylor

    (Imperial College School of Medicine)

  • S. Murray

    (Imperial College School of Medicine)

  • D. Thompson

    (University of Southampton)

  • A. Purvis

    (University of Southampton)

  • S. Kolstoe

    (University of Southampton)

  • S. P. Wood

    (University of Southampton)

  • P. N. Hawkins

    (Royal Free and University College Medical School)

Abstract

The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. This mechanism of drug action potently removes SAP from human amyloid deposits in the tissues and may provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.

Suggested Citation

  • M. B. Pepys & J. Herbert & W. L. Hutchinson & G. A. Tennent & H. J. Lachmann & J. R. Gallimore & L. B. Lovat & T. Bartfai & A. Alanine & C. Hertel & T. Hoffmann & R. Jakob-Roetne & R. D. Norcross & J., 2002. "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis," Nature, Nature, vol. 417(6886), pages 254-259, May.
    • Handle: RePEc:nat:nature:v:417:y:2002:i:6886:d:10.1038_417254a
    DOI: 10.1038/417254a
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/417254a
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/417254a?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:417:y:2002:i:6886:d:10.1038_417254a. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.